Fosun Pharma: Alzheimer's drug AR1001 hits Phase III goal in monotherapy group, misses overall
复星医药:控股子公司复星医药产业获独家选择权的在研药AR1001治疗早期阿尔茨海默病III期临床试验顶线数据于2026年11月16日首次公布,单药治疗人群主要终
Mixed trial data bear on whether Fosun takes up the licence option.
Fosun Pharma said top-line Phase III data for AR1001, an experimental drug for early Alzheimer's disease on which its subsidiary holds an exclusive option, were first released on Nov 16. The primary endpoint CDR-SB was statistically significant in the monotherapy population but not in the overall population. The subsidiary has not exercised the option and no licence has been agreed as of Nov 17.